Why I believe these 3 stocks will struggle in 2017

These three companies are in danger of generating losses for investors next year.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2017 is just around the corner and City analysts are picking their top stocks for the 12 months ahead. As well as the stocks I’m betting on for 2017, there are some companies I want to avoid next year as headwinds for these firms grow.

Indeed, I believe shares in Reckitt Benckiser (LSE: RB) will come under pressure next year as so-called ‘bond proxy’ stocks continue to fall out of favour with investors. 

Bond proxies are equities that have become an alternative to bonds as interest rates on bonds plunge into negative territory. Defensive companies such as Reckitt are prime proxies as their cash flows are considered safe, helping long-term dividend sustainability. However, as bond yields around the world are now pushing higher, these bond proxies are becoming less popular. 

It’s easy to see why. Yes, these are high-quality businesses, but the reach for yield has pushed their valuations up to record levels. Shares in Reckitt currently trade at a forward P/E of 22.9, down from last year’s 23.9 but still far above peer Unilever’s 19.7. I expect Reckitt’s shares to fall next year as investors rebalance away from bond proxies back towards bonds.

Revenues falling 

AstraZeneca (LSE: AZN) is another company I’m avoiding for 2017. This year, Astra’s most successful drug Crestor came off patent, and the full extent of this patent expiry isn’t yet known. 

According to City consensus, Astra’s top line is expected to fall by 5.8% next year due to management inability to rekindle the company’s pipeline growth. During the third quarter of this year, total product sales were down by 14% at $5bn, as Crestor and Nexium sales declined by 82% and 50% respectively in the US. For the quarter, the company reported a $1bn loss but earnings per share rose 4% to $0.80 thanks to a $453m tax benefit. 

As Astra’s earnings continue to contract with falling sales, it may be wise to avoid the drug maker next year.

Profits evaporate 

Finally, Rolls-Royce (LSE: RR) is a struggling engineer I’m avoiding next year. It has plenty of problems. From falling marine sales as a result of the oil price collapse, to faulty engines delivered to one of its largest customers Emirates, Rolls-Royce is struggling to get things right. What’s more, a new accounting change, whereby the company can’t immediately recognise revenue generated over the life of its engine service contracts immediately, will decimate profitability next year. Under the new accounting rules, Rolls’ 2015 profits would have been £900m lower than the £1.4bn reported. It’s not entirely clear how this change will impact profitability next year, but it’s evident the company will take a big hit to earnings. 

With profits set to tank and problems for the group brewing, Rolls might be one to avoid next year.

Rupert Hargreaves owns shares of Rolls-Royce. The Motley Fool UK owns shares of and has recommended Unilever. The Motley Fool UK has recommended AstraZeneca and Reckitt Benckiser. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Black woman using a debit card at an ATM to withdraw money
Investing Articles

Meet the FTSE 100’s newest bank stock

This FTSE 250 stock has skyrocketed nearly 900% over the past 60 months, earning it a place in the prestigious…

Read more »

Investing Articles

See what £10,000 invested in Shell shares 1 month ago is worth now

Harvey Jones looks at how Shell shares have fared over the past month and more importantly, what the long-term outlook…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Growth Shares

At its lowest level since July, here’s why I think the IAG share price is dead cheap

Jon Smith explains why the IAG share price has fallen over the past week but talks through the reasons why…

Read more »

Picture of an easyJet plane taking off.
Investing Articles

Will the easyJet share price rise 43% or 97% by this time next year?

City analysts believe easyJet's share price might almost double over the next year. Royston Wild considers the outlook for the…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

More great news for Rolls-Royce shares!

Rolls-Royce shares got a boost this week after some intriguing developments in the process of creating Europe's new fighter aircraft.

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Persimmon’s share price surges 7% on double boost! Can it keep rising?

Persimmon's share price is surging, up 11% at one point earlier on Tuesday. Could this be the start of a…

Read more »

This way, That way, The other way - pointing in different directions
Investing Articles

What on earth’s happening to the Greggs share price?

Harvey Jones says Greggs’ share price has shown surprising resilience in the recent stock market turmoil, but the FTSE 250…

Read more »

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

Barclays shares are down 18%. Time to consider buying?

Barclays’ shares have plummeted in recent weeks. Edward Sheldon looks at what’s going on and provides his view on the…

Read more »